|Mr. Ronald Dufficy BEC, FCPA||Interim Global Chief Exec. Officer||240.35k||N/A||N/A|
|Ms. Josephine Lorenz||Global CFO & Group Financial Controller||N/A||N/A||N/A|
|Glen Zurcher||Account Director of Investor Relations Department||N/A||N/A||N/A|
|Ms. Teresa Cleary||Gen. Counsel & Company Sec.||N/A||N/A||N/A|
|Mr. Rob Hasselman||Pres of Americas||N/A||N/A||N/A|
|Ms. Beata Silber||Global Head of R&D and Innovation||N/A||N/A||N/A|
|Ms. Kim Bradley-Ware||Joint Company Sec.||N/A||N/A||N/A|
Elixinol Wellness Limited, through its subsidiaries, manufactures and distributes hemp derived nutraceuticals, cosmetics, and food products under the Elixinol and Hemp Foods Australia brands in the Americas, Europe, and Australia. It offers hemp derived cannabidiol and food products, dietary supplements, topicals, and skincare products. The company was formerly known as Elixinol Global Limited and changed its name to Elixinol Wellness Limited in May 2021. The company was incorporated in 2017 and is headquartered in Sydney, Australia.
Elixinol Wellness Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.